- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00005095
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study
RATIONALE: To improve strategies for detection and prevention of early-stage disease.
PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- To identify and develop highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies.
- To identify new prevention approaches and therapies.
- To identify measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer.
OUTLINE: Subjects undergo periodic specimen and data collection for research studies, including molecular, biochemical, functional, and genetic marker studies. Participants may have samples of blood, tissue, or body fluids (such as ascites, pleural fluid or urine), or any combination of the aforementioned samples obtained to develop tumor markers to detect early stage or recurrent ovarian cancer.
The results from the biomarker research studies will not be reported to the patient or the physician. In the future, if any of the experimental tumor markers are found to be effective in detecting early stage ovarian cancer, and the patient's result is abnormal, the patient and physician will be notified.
Subjects may be asked to complete a combination of questionnaires designed to evaluate psychological functioning among women enrolled in a comprehensive ovarian cancer early detection program who are at increased risk for developing disease as compared to women currently diagnosed with ovarian cancer.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Kisha Hope
- Phone Number: 312-503-3857
- Email: kisha.hope@northwestern.edu
Study Contact Backup
- Name: Anne Grace
- Phone Number: 312-503-4165
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611-3013
- Recruiting
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
Contact:
- Clinical Trials Office - Robert H. Lurie Comprehensive Cancer
- Phone Number: 312-695-1301
- Email: cancer@northwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
DISEASE CHARACTERISTICS:
Meets one of the following criteria:
Considered to be at increased risk for developing ovarian cancer, as defined by one of the following:
- Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer
- Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor
- A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer
- Increased risk as deemed by a certified genetic counselor
Undergoing surgery for a gynecologic condition, including any of the following:
- Diagnosis of a reproductive cancer
- Benign gynecological condition (e.g., uterine leiomyomata, endometriosis, pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts)
- Highly suspicious adnexal mass
- Risk-reducing prophylactic oophorectomy
PATIENT CHARACTERISTICS:
Age
- Between the ages of 18 and 80
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
High Risk for Ovarian Cancer
Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
|
Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects.
Clinical data will also be collected.
Other Names:
Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
Subjects will be assessed for high risk factors.
Other Names:
|
Suspected or diagnosed gynecological condition
Women who are planning to undergo surgery for their gynecological condition
|
|
Control Group
Healthy subjects with no history of cancer and at general risk.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The development of ultrasound and serum tumor markers for the detection and management of ovarian cancer and other
Time Frame: 1 year
|
To identify markers to allow for presymptomatic testing for ovarian and other gynecological malignancies
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
new prevention approaches and therapies for risk assessment
Time Frame: 1 year
|
To identify new prevention approaches and therapies by researching and reviewing the risk of developing disease.
|
1 year
|
The develop of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer
Time Frame: 1 year
|
To identify the measurements to improve the quality of life for women at increased risk for developing the disease
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Lee P. Shulman, MD, Robert H. Lurie Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Connective Tissue Diseases
- Fallopian Tube Diseases
- Neoplasms, Connective Tissue
- Vaginal Diseases
- Vulvar Diseases
- Neoplasms, Muscle Tissue
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Sarcoma
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Endometrial Neoplasms
- Carcinoma, Ovarian Epithelial
- Vulvar Neoplasms
- Leiomyoma
- Myofibroma
- Vaginal Neoplasms
Other Study ID Numbers
- NU 99G8
- P30CA060553 (U.S. NIH Grant/Contract)
- NU-99G8 (Other Identifier: Northwestern University IRB)
- NCI-G00-1753 (Other Grant/Funding Number: NCI)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Synovial SarcomaUnited States
Clinical Trials on screening questionnaire administration
-
University College, LondonMedical Research Council; Cancer Research UK; National Institute for Health Research... and other collaboratorsCompleted
-
National Cancer Institute (NCI)Active, not recruitingColon Carcinoma | Rectal CarcinomaUnited States
-
Netherlands Open UniversityMaastricht University Medical Center; Dutch Cancer Society; Maastro Clinic, The... and other collaboratorsCompletedBreast Cancer | Colorectal Cancer | Lung Cancer | Prostate Cancer | Non-Hodgkin Lymphoma | Bladder Cancer | Cervix Cancer | Cancer of Skin | Cancer of EndometriumNetherlands
-
Barts and the London School of Medicine and DentistryCompletedPrecancerous Condition | Health Status UnknownUnited Kingdom
-
Thomas Jefferson UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
US Department of Veterans AffairsNational Cancer Institute (NCI)UnknownEsophageal Cancer | Precancerous ConditionUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Vanderbilt University; Lucille P. Markey Cancer...Completed
-
Duke UniversityTerminatedColorectal CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCervical Carcinoma | Human Papillomavirus Infection | Health Status Unknown | Cervical Intraepithelial Neoplasia Grade 2/3 | Stage 0 Cervical Cancer | Atypical Squamous Cell of Undetermined Significance | Low Grade Cervical Squamous Intraepithelial NeoplasiaUnited States
-
Susanne WalitzaRecruitingSubstance Use DisordersSwitzerland